This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tianjin Ringpu Bio-Technology Co.,Ltd. completed the acquisition of Baoding Shoujun Technology Co., Ltd. from Yao Lili, Zhang Xiaoqin and Tianjin Ruichuang Biotechnology Partnership (Limited Partnership). CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tianjin Ringpu Bio-Technology Co.,Ltd. agreed to acquire Baoding Shoujun Technology Co., Ltd. from Yao Lili, Zhang Xiaoqin and Tianjin Ruichuang Biotechnology Partnership (Limited Partnership) for CNY 230 million. CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Tianjin Ringpu Bio-Technology Co.,Ltd.'s Equity Buyback Plan announced on October 27, 2023. CI
Tianjin Ringpu Bio-Technology Co.,Ltd.'s Equity Buyback announced on October 27, 2023, has closed with 3,689,608 shares, representing 0.8% for CNY 59.99 million. CI
Tranche Update on Tianjin Ringpu Bio-Technology Co.,Ltd.'s Equity Buyback Plan announced on October 27, 2023. CI
Tianjin Ringpu Bio-Technology Co.,Ltd. announces an Equity Buyback for CNY 80 million worth of its shares. CI
Tianjin Ringpu Bio-Technology Co.,Ltd. authorizes a Buyback Plan. CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Luzhu Biotechnology Ties Up With Tianjin Ringpu to Develop Pet Vaccines, Drugs MT
Beijing Luzhu Biotechnology Co., Ltd. and Tianjin Ringpu Bio-Technology Co., Ltd. Announces Strategic Cooperation Framework Agreement CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tianjin Ringpu Bio-Technology Co.,Ltd. signed an agreement to acquire 15% stake in Fujian Sunvet Biotechnology Co., Ltd. from Guo Haiyan and 16 natural person shareholders for CNY 63 million. CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Announces Executive Appointments CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Tianjin Ringpu Bio-Technology to Unlock Shares Issued in Grant Scheme MT
Tianjin Ringpu Bio-Technology Raises $207 Million From Private Placement MT
Tianjin Ringpu Bio-Technology Co.,Ltd. agreed to acquire 20% stake in Beijing Challenge Bio-Technology Co., Ltd. from Hangzhou Zhongyu Zhichen Investment Management Partnership for CNY 48 million. CI
Hunan Sinoland Bio-pharmacy CO.,Ltd announced that it has received CNY 80 million in funding from Tianjin Ringpu Bio-Technology Co.,Ltd. CI
Tianjin Ringpu Bio-Technology Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chart Tianjin Ringpu Bio-Technology Co.,Ltd.
More charts
Tianjin Ringpu Bio-Technology Co Ltd is a China-based company serving the animal health industry. The Company's main business areas are the research and development, production and sales of veterinary biological products, veterinary pharmaceutical preparations (chemicals, traditional Chinese veterinary medicines, disinfectants, and others), veterinary raw materials, veterinary functional additives, and provision of overall prevention and control of animal diseases. The Company's products include pharmaceuticals, vaccines, disinfectants, cleaning agents, and functional additives for pigs, chickens, waterfowl, cattle, sheep and pets, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.28 CNY
Average target price
21.14 CNY
Spread / Average Target
+38.32%
Consensus
  1. Stock Market
  2. Equities
  3. 300119 Stock
  4. News Tianjin Ringpu Bio-Technology Co.,Ltd.
  5. Tianjin Ringpu Bio-Technology to Unlock Shares Issued in Grant Scheme